AbbVie
AbbVie turns to tau for Alzheimer’s in $1.1bn deal
February 21, 2018Research and Development, Sales and Marketing AbbVie, Alzheimer's, Voyager, biotech, drugs, pharma, pharmaceutical
Sailing against the prevailing winds in the Alzheimer’s disease space, AbbVie has launched a deal worth a potential $1.1 billion …
Death in trial blackens AbbVie’s positive rheumatoid arthritis data
December 21, 2017Research and Development AbbVie, biotech, drugs, pharma, pharmaceutical, rheumatoid arthritis
AbbVie posted strong results from its Phase 3 trial into its treatment for rheumatoid arthritis, upadacitinib, but discussions of the …
AbbVie posts strong psoriasis data but can it stand out from crowd?
December 5, 2017Manufacturing and Production, Research and Development AbbVie, biotech, drugs, pharma, pharmaceutical
AbbVie revealed that its IL-23 inhibitor, risankizumab, had successfully met all of its endpoints in a Phase 3 trials into …
AbbVie’s psoriasis drug smashes all endpoints
October 26, 2017Medical Communications, Research and Development AbbVie, IL-23, biotech, drugs, pharma, pharmaceutical, risankizumab
AbbVie already know well what it’s like to have a lead candidate in the psoriasis field, after having Humira sat …
AbbVie hit with $140m fine over fraudulent marketing of Androgel
October 6, 2017Medical Communications, Sales and Marketing AbbVie, androgel, biotech, drugs, pharma, pharmaceutical
AbbVie has been stung with a $140 million damages award to a man that suffered a heart attack after using …
AbbVie adds biologic production capability to Singapore facility
October 4, 2017Manufacturing and Production, Research and Development AbbVie, Singapore, biologics, pharma, pharmaceuticals
AbbVie has expanded the operational capability of its facility located at the Tuas Biomedical Park in Singapore with the addition …
Five more biosimilar-free years for AbbVie’s megablockbuster
September 28, 2017Medical Communications, Sales and Marketing AbbVie, Amgen, Amjevita, Humira, biotech, drugs, pharma, pharmaceutical
Humira is the key drug for AbbVie, and one the company hopes it will be able to push into the …
Roche and AbbVie’s leukaemia combo smashes Phase 3 endpoint
September 19, 2017Manufacturing and Production, Research and Development AbbVie, Rituxan, Roche, Venclexta, Venclyxto, leukaemia, pharma, pharmaceutical
Venclexta/Venclyxto (venetoclax), Roche and AbbVie’s oral B-cell lymphoma-2 (BCL-2) inhibitor, successfully met its primary endpoint in Phase 3 trials, providing …
Sandoz psoriasis biosimilar tops reference product Humira in latest Phase 3 data
September 15, 2017Medical Communications, Research and Development AbbVie, Humira, Novartis, Sandoz, adalimumab, biosimilar, biosimilars, pharma, pharmaceutical
Sandoz, the biologics and generics division of Novartis, has unveiled new Phase 3 data confirming the efficacy and safety profile …
Questions raised after two deaths in AbbVie arthritis study
September 12, 2017Manufacturing and Production, Research and Development AbbVie, biotech, drugs, pharma, pharmaceutical, rheumatoid arthritis
AbbVie’s rheumatoid arthritis drug, upadacitinib, is the company’s big plan to manage the inevitable loss of sales from Humira, as …
New potential blockbuster RA treatment enters European market
June 27, 2017Sales and Marketing AbbVie, Humria, Kevzara, Regeneron, Sanofi
The world’s biggest selling drug, AbbVie’s Humira with $16 billion in sales last year, has a new rival in the …
AbbVie loses $15 million Depakote birth-defect case
June 12, 2017Sales and Marketing AbbVie, Abbott, Depakote
Court cases for the anti-seizure medicine Depakote continue to rumble on for AbbVie, with the latest case finding AbbVie liable …
AbbVie posts promising data on RA drug
June 8, 2017Research and Development AbbVie, JAK inhibitor
AbbVie posted results on upadacitinib, the latest drug in its pipeline for rheumatoid arthritis (RA) and the results have given …
Abbvie names new General Managers for UK and France
June 2, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, appointment
Abbvie has announced a double appointment across its UK and French operations, naming Jérôme Bouyer as its UK General Manager, …
AbbVie suffers knock to Humira patent
May 19, 2017Medical Communications, Sales and Marketing AbbVie, Humira, patents
Humira is the largest selling pharmaceutical drug in the world. The treatment for rheumatoid arthritis brought in over $16 billion …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
